XML 61 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
REVENUE (Tables)
 12 Months Ended
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]  
Summary of Activity in Accrued Rebates and Chargebacks, Returns, Wholesaler Service Fees and Prompt Pay Discounts
The following table provides a summary of activity with respect to the Company’s sales related allowances and accruals related to EXPAREL for the years ended December 31, 2021, 2020 and 2019, as well as ZILRETTA for the year ended December 31, 2021 (in thousands):
Returns AllowancesPrompt Payment DiscountsService FeesVolume Rebates and ChargebacksGovernment RebatesTotal
Balance at December 31, 2018$344 $779 $1,167 $1,010 $— $3,300 
  Provision783 8,426 6,267 11,475 — 26,951 
  Payments/Adjustments(587)(8,243)(5,948)(10,669)— (25,447)
Balance at December 31, 2019540 962 1,486 1,816 — 4,804 
  Provision794 8,541 6,437 12,345 — 28,117 
  Payments/Adjustments(311)(8,496)(6,755)(12,561)— (28,123)
Balance at December 31, 20201,023 1,007 1,168 1,600 — 4,798 
   Provision3,095 10,388 10,112 17,101 1,139 41,835 
   Payments/Adjustments(757)(10,217)(7,644)(15,207)(378)(34,203)
Balance at December 31, 2021$3,361 $1,178 $3,636 $3,494 $761 $12,430 
Disaggregation of Revenue
The following table represents disaggregated net product sales in the periods presented as follows (in thousands):
Year Ended December 31,
202120202019
 Net product sales:
      EXPAREL$506,515 $413,338 $407,877 
      ZILRETTA12,683 — — 
      iovera°16,162 8,817 7,896 
      Bupivacaine liposome injectable suspension3,606 4,459 3,153 
 Total net product sales$538,966 $426,614 $418,926